We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$595M
AUM Growth
-$61.1M
(-9.3%)
Cap. Flow
-$55.7M
Cap. Flow
% of AUM
-9.37%
Top 10 Holdings %
Top 10 Hldgs %
57.86%
Holding
38
New
10
Increased
10
Reduced
16
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$32.4M |
| 2 |
AGN
Allergan plc
AGN
|
+$11.2M |
| 3 |
Cigna
CI
|
+$7.92M |
| 4 |
Boston Scientific
BSX
|
+$6.4M |
| 5 |
SRCL
Stericycle Inc
SRCL
|
+$5.55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$48.2M |
| 2 |
Baxter International
BAX
|
+$15.4M |
| 3 |
SHPG
Shire pic
SHPG
|
+$14.1M |
| 4 |
Elevance Health
ELV
|
+$13.1M |
| 5 |
Abbott
ABT
|
+$10.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.59% |
| 2 | Industrials | 0.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tenet Healthcare
THC
$16.7B
| $7.06M | 1.19% |
465,621
-49,559
| -10% | -$697K |
|
27
DaVita
DVA
$15B
| $6.26M | 1.05% |
+86,680
| New | +$5.33M |
|
|
SRCL
28
DELISTED
Stericycle Inc
SRCL
| $5.56M | 0.93% |
+81,800
| New | +$5.55M |
|
29
Viatris
VTRS
$19.8B
| $5.56M | 0.93% |
+131,361
| New | +$5.02M |
|
|
MNTA
30
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $3.84M | 0.64% |
275,024
-45,031
| -14% | -$609K |
|
31
Ionis Pharmaceuticals
IONS
$8.75B
| $3.12M | 0.53% |
+62,100
| New | +$3.41M |
|
|
ONCE
32
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $2.7M | 0.45% |
+52,500
| New | +$3.77M |
|
|
PTLA
33
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.43M | 0.41% |
+50,000
| New | +$2.53M |
|
|
JUNO
34
DELISTED
Juno Therapeutics, Inc.
JUNO
| $1.98M | 0.33% |
+43,400
| New | +$2.16M |
|
|
RDUS
35
DELISTED
Radius Health, Inc.
RDUS
| $1.66M | 0.28% |
52,173
+13,000
| +33% | +$408K |
|
36
Alnylam Pharmaceuticals
ALNY
$36.4B
| $1.19M | 0.2% |
+9,400
| New | +$1.18M |
|
|
ACH
37
Accendra Health
ACH
$254M
| – | – |
-175,874
| Closed | -$5.14M |
|
|
IPXL
38
DELISTED
Impax Laboratories, Inc.
IPXL
| – | – |
-422,261
| Closed | -$8.57M |
|
Similar funds
AFWM
MP
DS
RS
DF
OGM
CPIM
MPPLM
Sector Gamma AS's Q4 2017 Portfolio in Review
As of Q4 2017, Sector Gamma AS held 38 positions worth $595M, down 9.3% from $656M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Sector Gamma AS withdrew a net $55.7M in Q4 2017, closing 2 positions and reducing 16 holdings. Its most notable exit was Impax Laboratories, Inc., an estimated $8.57M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials.
Against the trend, Sector Gamma AS opened a new position in Merck worth $31.4M.
- Sector Gamma AS's largest Q4 2017 buy was Merck: 585,308 shares worth $31.4M.
- Sector Gamma AS added most to Cigna in Q4 2017, an estimated $7.92M increase.
- Sector Gamma AS's biggest Q4 2017 reduction was Eli Lilly, cutting an estimated $48.2M.
- Sector Gamma AS fully exited Impax Laboratories, Inc. in Q4 2017, selling an estimated $8.57M.
- Sector Gamma AS's ten largest holdings make up 58% of its $595M portfolio in Q4 2017.
- Sector Gamma AS opened 10 new positions and closed 2 in Q4 2017.
- Sector Gamma AS's portfolio value fell 9.3% quarter-over-quarter to $595M.
Based on Sector Gamma AS's 13F filing for Q4 2017, filed 12 Feb 2018.